World Kidney Day on March 8th 2012 provides a chance to reflect on the success of kidney transplantation as a therapy for end stage kidney disease that surpasses dialysis treatments both for the quality and quantity of life that it provides and for its cost effectiveness. Anything that is both cheaper and better, but is not actually the dominant therapy, must have other drawbacks that prevent replacement of all dialysis treatment by transplantation. The barriers to universal transplantation as the therapy for end stage kidney disease include the economic limitations which, in some countries place transplantation, appropriately, at a lower priority than public health fundamentals such as clean water, sanitation and vaccination. Even in high income countries the technical challenges of surgery and the consequences of immunosuppression restrict the number of suitable recipients, but the major finite restrictions on kidney transplantation rates are the shortage of donated organs and the limited medical, surgical and nursing workforces with the required expertise. These problems have solutions which involve the full range of societal, professional, governmental and political environments. World Kidney Day is a call to deliver transplantation therapy to the one million people a year who have a right to benefit.

1.
Murray JE: Ronald Lee Herrick Memorial: June 15, 1931-December 27, 2010. Am J Transplant 2011;11:419.
3.
Shimmura H, Tanabe K, Ishida H, Tokumoto T, Ishikawa N, Miyamoto N, Shirakawa H, Setoguchi K, Nakajima I, Fuchinoue S, Teraoka S, Toma H: Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 2005;80:985–988.
4.
Peng A, Vo A, Jordan SC: Transplantation of the highly human leukocyte antigen-sensitized patient: long-term outcomes and future directions Transplantation Reviews 2006;20:46–156.
5.
Warren DS, Montgomery RA: Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange. Immunol Res 2010;47:257–264.
6.
Weber CLC, Rush DN, Jeffery JR, Cheang M, Karpinski ME: Kidney transplantation outcomes in Canadian aboriginals. Am J Transplantation 2006;6:1882–1889.
7.
Gordon EJ, Ladner DP, Caicedo JC, Franklin J: Disparities in kidney transplant outcomes: A review. Semin Nephrol 2010;30:81–89.
8.
Collins JF: Kidney disease in Maori and Pacific people in New Zealand. Clin Nephrol 2010;74:S61–S65.
9.
Rizvi SAH, Naqvi SAA, Zafar MN, Hussain Z, Hashmi A, Hussain M, Akhtar F, Ahmed E: Living related renal transplants with lifelong follow-up. A model for the developing world. Clin Nephrol 2010;74(suppl 1):S142–S149.
10.
Monteon FJ, Gomez B, Valdespino C, Chavez S, Sandoval M, Flores A, et al: The kidney transplant experience at Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara México. Clin Traspl 2003;165–174.
11.
Jha V: Current status of end-stage disease care in South Asia. Ethn Dis 2009;1(suppl 1):S27–S32.
12.
Wolfe RA, Ashby VB, Milford EL, et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. New Eng J Med 1999;341:1725–1730
13.
Sakhuja V, Sud K: End-stage renal disease in India and Pakistan: Burden of disease and management issues. Kidney Int 2003;83: S115– S118.
14.
Rizvi SAH, Naqvi SAA, Zafar MN et al: A Renal Transplantation Model for developing countries. Am J Transplant 2011:11:2302–2307.
15.
Sud K, Sakhuja V, Pandey R, Singh B, Kohli HS, Jha V, Gupta KL: Bioequivalence of the microemulsive preparations of cyclosporine in renal transplant recipients with stable graft function. Indian J Nephrol 1999;9:83–91.
16.
Meier-Kriesche HU, Kaplan B: Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes. Transplantation 2002;74:1377–1381.
17.
Kasiske BL, Snyder JJ, Matas MD, et al: Pre-emptive kidney transplantation: The advantage and the advantaged. J Am Soc Nephrol 2002;13:1358–1356.
19.
Yeates K: Health Disparities in renal disease in Canada. Semin Nephrol 2010;30:12–18.
20.
Alexander GC, Sehgal AR: Barriers to cadaveric renal transplantation among blacks, women, and the poor. JAMA 1998;280:1148–1152.
21.
McDonald S: Incidence and treatment of ESRD among indigenous peoples of Australasia. Clin Nephrol 2010;74(suppl 1):S28–S31.
22.
Garcia-Garcia G, Renoirte-Lopez K, Marquez-Magaña I: Disparities in renal care in Jalisco, Mexico. Semin Nephrol 2010;30:3–7.
23.
Gordon EJ, Ladner DP, Caicedo JC, Franklin J: Disparities in kidney transplant outcomes: A review. SeminNephrol 2010;30:81–89.
24.
3rd Global WHO Consultation March 2010: Organ Donation and Transplantation: Striving to Achieve Self-Sufficiency. Transplantation 2011;91(11S):S27–S114.
25.
Bernat JJ, D’Alesandro AM, Port FK, Bleck TP, Heard SO, et al: Report of a National conference on donation after cardiac death. Am J Transplant 2006;6:281–291.
26.
Abraham G, John GT, Sunil S, Fernando EM, Reddy YNV: Evolution of renal transplantation in India over the last four decades. NDT Plus 2010;3:203–207.
27.
Shimazono Y: Thestate of the international organ trade: a provisional picture based on integration of available information. Bull World Health Organ 2007;85:955–962.
28.
World Health Assembly 44/1991/REC/1. Annex 6.
29.
World Health Assembly 63.22/2010 http://www.who.int/transplantation/Guiding_PrinciplesTransplantation_WHA63.22en.pdf. Accessed 29/11/2011.
30.
Participants in the International Summit onTransplantTourism and Organ Trafficking Convened by the Transplantation Society and International Society of Nephrology in Istanbul, Turkey, April 30-May 2, 2008. The Declaration of Istanbul on organ trafficking and transplant tourism. Transplantation 2008;86:1013–1018.
31.
Delmonico FL, Domínguez-Gil B, Matesanz R, Noel L: A call for government accountability to achieve nationalself-sufficiency in organdonation and transplantation. Lancet 2011 Oct 15.
32.
United Nations General Assembly. Political declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases A/66/L.1, September 16, 2011.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.